Τίτλος:
High prevalence of anti-pf4 antibodies following chadox1 ncov-19 (Azd1222) vaccination even in the absence of thrombotic events
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
It is unclear whether the ChAdOx1 nCov-19 vaccine can induce the development of anti-PF4 antibodies in vaccinated individuals who have not developed thrombosis. The aim of this prospective study was to evaluate the presence of antibodies against heparin/PF4 in adults who received a first dose of the ChAdOx1 nCov-19 vaccine, and correlate them with clinical data and antibody responses to the vaccine. We detected non-platelet activating anti-PF4 antibodies in 67% (29/43) of the vaccinated individuals on day 22 following the first dose of the ChAdOx1 nCov-19 vaccine, though these were detected in low titers. Furthermore, there was no correlation between the presence of anti-PF4 IgG antibodies and the baseline clinical characteristics of the patients. Our findings suggest that the ChAdOx1 nCov-19 vaccine can elicit anti-PF4 antibody production even in recipients without a clinical manifestation of thrombosis. The presence of anti-PF4 antibodies was not sufficient to provoke clinically evident thrombosis. Our results offer an important insight into the ongoing investigations regarding the underlying multifactorial pathophysiology of thrombotic events induced by the ChAdOx1 nCov-19 vaccine. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Terpos, E.
Politou, M.
Ntanasis-Stathopoulos, I.
Karalis, V.
Merkouri, E.
Fotiou, D.
Gavriatopoulou, M.
Malandrakis, P.
Kastritis, E.
Trougakos, I.P.
Dimopoulos, M.A.
Λέξεις-κλειδιά:
angiotensin converting enzyme 2; chadox1 ncov 19; heparin; immunoglobulin G antibody; neutralizing antibody; thrombin receptor activating peptide; thrombocyte factor 4, adult; antibody response; Article; body mass; clinical article; controlled study; coronavirus disease 2019; diabetes mellitus; enzyme linked immunosorbent assay; female; gastroesophageal reflux; hematologic malignancy; human; hyperlipidemia; hypertension; hypothyroidism; male; middle aged; obesity; pathophysiology; prevalence; prospective study; Severe acute respiratory syndrome coronavirus 2; thrombocyte aggregation; thrombosis; vaccination
DOI:
10.3390/vaccines9070712
